Status:
COMPLETED
Vascular Effect of CIMICIFUGA RACEMOSA
Lead Sponsor:
Federal University of Minas Gerais
Conditions:
Postmenopausal Symptoms
Eligibility:
FEMALE
45-65 years
Phase:
NA
Brief Summary
Postmenopausal women with vascular symptoms will use Cimifuga Racemosa or Placebo and the effects will be evaluated using Flow-Mediated Dilatation of the brachial artery.
Detailed Description
The interruption of the secretion of ovarian steroids after menopause, determines a change in the vascular pattern in several levels. Thus, several vascular effects might interfere with women's health...
Eligibility Criteria
Inclusion
- Women with postmenopausal vascular symptoms
- Women without menstrual cycles within the last 12 months and follicle stimulating hormone (FSH) \> 30 International Units(IU)/Litre
- Women that were not using drugs with potential vascular effect within the last 1 year
- Women that were not using hormone replacement therapy within the last 1 year
Exclusion
- Smoking
- Blood Pressure \> 160/90 mm Hg.
- Breast and or endometrial cancer
- History of acute myocardial infarction
- Diabetes
- Vaginal bleeding of any origin
- Hepatic disease
- Thrombophlebitis or thromboembolic disorders
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03786809
Start Date
June 1 2016
End Date
May 1 2019
Last Update
August 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clinicas - Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil, 30130100